Phospho-EGFR (Tyr1069) Polyklonaler Antikörper

Phospho-EGFR (Tyr1069) Polyklonal Antikörper für WB, ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human

Anwendung

WB, ELISA

Konjugation

Unkonjugiert

Kat-Nr. : 30277-1-AP

Synonyme

EGFR, ERBB, ErbB1, HER1, mENA, Phospho-EGFR (Tyr1045), Phospho-EGFR (Tyr1069), PIG61, Proto oncogene c ErbB 1

---

Galerie der Validierungsdaten

• 

  WB analysis using 30277-1-AP

  Non-treated HeLa and EGF treated HeLa cells were subjected to SDS PAGE followed by western blot with 30277-1-AP (Phospho-EGFR (Tyr1069) antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours. The membrane was stripped and re-blotted with Vinculin antibody as loading control.

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: EGF treated HeLa cells

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:500-1:2000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Produktinformation

30277-1-AP bindet in WB, ELISA Phospho-EGFR (Tyr1069) und zeigt Reaktivität mit human

• Getestete Reaktivität: human
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Polyklonal
• Typ: Antikörper
• Immunogen: Peptid
• Vollständiger Name: epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian)
• Berechnetes Molekulargewicht: 1210 aa, 134 kDa
• Beobachtetes Molekulargewicht: 170 kDa
• GenBank-Zugangsnummer: BC094761
• Gene symbol: EGFR
• Gene ID (NCBI): 1956
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Antigen-Affinitätsreinigung
• Lagerungspuffer: PBS mit 0.02% Natriumazid und 50% Glycerin pH 7.3.
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

Epidermal Growth Factor Receptor (EGFR) is one of the receptor tyrosine kinases (RTKs), members of the ErbB/HER family which consists of ErbB1 (EGFR or HER1), ErbB2 (HER2 or Neu), ErbB3 (HER3), and ErbB4 (HER4). Aberrant activation of EGFR is among the most common oncogenic driving events in human cancer, which is mediated largely through different classes of genomic alterations within the EGFR gene. Phosphorylation of EGFR Tyr1069 acts as the degron of EGFR and is recognized by c-Cbl, enhancing the ubiquitination and degradation of EGFR. EGFR stability is tightly regulated upon EGF stimulation. (PMID: 35164092, PMID: 29464683, PMID: 37085908). Some scientists call EGFR Tyr1069 as EGFR Tyr1045, the site where the signaling peptide is removed.